Dr Reddy's Labs expects strong product pipeline in North America for FY25

Published On 2024-05-09 12:17 GMT   |   Update On 2024-05-09 12:17 GMT
Advertisement

Bengaluru: Dr. Reddy's Laboratories, based in India, forecasts a strong product lineup for its key market in North America in the fiscal year 2024-25, the generic pharmaceutical firm has declared. This announcement came after it reported fourth-quarter profits that surpassed expectations.

Lenalidomide, the company's generic version of Bristol-Myers Squibb's blockbuster cancer drug Revlimid, will continue to be a meaningful contributor for the next three quarters, the drugmaker said in a post earnings media call.

Advertisement
The drug has been persistently boosting Dr Reddy's U.S. sales since its launch in 2022.
Other generic drugmakers such as Cipla, Sun Pharma and Zydus Lifesciences have also benefitted from rising sales of their own copycat versions of Revlimid in the U.S.
According to Reuters report, Bristol Myers is facing pressure from generic competition for Revlimid, once its top-selling drug.
Meanwhile, generic drugmakers are grappling with pricing pressures amid intensifying competition.
"Price erosion trends are stable," Dr Reddy's CFO Parag Agarwal said, adding he does not see any structural impact or change in the market.
Dr Reddy's consolidated net profit for three months ended March 31 rose 36.5% from a year earlier to 13.10 billion rupees (about $157 million), beating analysts' average estimates of 12.42 billion rupees, per LSEG data.
The drugmaker's total revenue climbed 13% to 71.14 billion, in line with analysts' expectations, led by a 29% climb in the North American generics business, its biggest segment. Sales in Europe rose 5%.
The company said M V Narasimham, who is currently deputy CFO, will take over as the finance chief from Parag Agarwal, who will retire on July 31.
Rival Cipla will report its fourth-quarter results on Friday.
Read also: Dr Reddy's Labs unveils Doxycycline Capsules, 40 mg in US to treat inflammatory lesions of rosacea
Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News